Role of post-translational modifications on the alpha-synuclein aggregation-related pathogenesis of Parkinson’s disease

키워드

참고문헌 (124)

1. Klein C, "Genetics of Parkinson’s disease", Cold Spring Harb Perspect Med, 2, pp.a008888~ (2012)
2. Polymeropoulos MH, "Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease", Science, 276, pp.2045~2047 (1997)
3. Emamzadeh FN, "Alpha-synuclein structure, functions, and interactions", J Res Med Sci, 21, pp.29~ (2016)
4. Spillantini MG, "alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with lewy bodies", Proc Natl Acad Sci U S A, 95, pp.6469~6473 (1998)
5. Trojanowski JQ, "Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy", Neuropathol Appl Neurobiol, 33, pp.615~620 (2007)
6. McCann H, "alpha-Synucleinopathy phenotypes", Parkinsonism Relat Disord, 20(Suppl 1), pp.S62~S67 (2014)
7. Nishie M, "A quantitative investigation of neuronal cytoplasmic and intranuclear inclusions in the pontine and inferior olivary nuclei in multiple system atrophy", Neuropathol Appl Neurobiol, 30, pp.546~554 (2004)
8. Fauvet B, "alpha-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer", J Biol Chem, 287, pp.15345~15364 (2012)
9. Bartels T, "alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation", Nature, 477, pp.107~110 (2011)
10. Lashuel HA, "Alpha-synuclein, especially the Parkinson’s disease-associated mutants, forms pore-like annular and tubular protofibrils", J Mol Biol, 322, pp.1089~1102 (2002)
11. Cremades N, "Direct observation of the interconversion of normal and toxic forms of alpha-synuclein", Cell, 149, pp.1048~1059 (2012)
12. Chen SW, "Structural characterization of toxic oligomers that are kinetically trapped during alpha-synuclein fibril formation", Proc Natl Acad Sci U S A, 112, pp.E1994~ (2015)
13. Mahul-Mellier AL, "The process of Lewy body formation, rather than simply alpha-synuclein fibrillization, is one of the major drivers of neurodegeneration", Proc Natl Acad Sci U S A, 117, pp.4971~4982 (2020)
14. Danzer KM, "Different species of alpha-synuclein oligomers induce calcium influx and seeding", J Neurosci, 27, pp.9220~9232 (2007)
15. Fusco G, "Structural basis of membrane disruption and cellular toxicity by alpha-synuclein oligomers", Science, 358, pp.1440~1443 (2017)
16. Peelaerts W, "alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration", Nature, 522, pp.340~344 (2015)
17. Li JY, "Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation", Nat Med, 14, pp.501~503 (2008)
18. Braak H, "Stages in the development of Parkinson’s disease-related pathology", Cell Tissue Res, 318, pp.121~134 (2004)
19. Volpicelli-Daley LA, "Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death", Neuron, 72, pp.57~71 (2011)
20. Yasuda T, "alphaSynuclein and neuronal cell death", Mol Neurobiol, 47, pp.466~483 (2013)
21. Benskey MJ, "The contribution of alpha synuclein to neuronal survival and function-Implications for Parkinson’s disease", J Neurochem, 137, pp.331~359 (2016)
22. Sherer TB, "An in vitro model of Parkinson’s disease : linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage", J Neurosci, 22, pp.7006~7015 (2002)
23. Scudamore O, "Increased oxidative stress exacerbates alpha-synuclein aggregation in vivo", J Neuropathol Exp Neurol, 77, pp.443~453 (2018)
24. Musgrove RE, "Oxidative stress in vagal neurons promotes parkinsonian pathology and intercellular alpha-synuclein transfer", J Clin Invest, 129, pp.3738~3753 (2019)
25. Xilouri M, "alpha-Synuclein and protein degradation systems : a reciprocal relationship", Mol Neurobiol, 47, pp.537~551 (2013)
26. 이공주, "Post-translational Modifications and Their Biological Functions: Proteomic Analysis and Systematic Approaches", BMB reports, 37(1), pp.35~44 (2004), 한국생화학분자생물학회
27. Maltsev AS, "Impact of N-terminal acetylation of alpha-synuclein on its random coil and lipid binding properties", Biochemistry, 51, pp.5004~5013 (2012)
28. Kang L, "N-terminal acetylation of alphasynuclein induces increased transient helical propensity and decreased aggregation rates in the intrinsically disordered monomer", Protein Sci, 21, pp.911~917 (2012)
29. Bartels T, "Nalpha-acetylation of alpha-synuclein increases its helical folding propensity, GM1 binding specificity and resistance to aggregation", PLoS One, 9, pp.e103727~ (2014)
30. Watson MD, "N-terminal acetylation affects alpha-synuclein fibril polymorphism", Biochemistry, 58, pp.3630~3633 (2019)
31. Dikiy I, "N-terminal acetylation stabilizes N-terminal helicity in lipid-and micelle-bound alpha-synuclein and increases its affinity for physiological membranes", J Biol Chem, 289, pp.3652~3665 (2014)
32. Lorentzon E, "Differential effects of Cu(2+)and Fe(3+)ions on in vitro amyloid formation of biologically-relevant alpha-synuclein variants", Biometals, 33, pp.97~106 (2020)
33. Lima VA, "Role of Parkinson’s disease-linked mutations and N-terminal acetylation on the oligomerization of alphasynuclein Induced by 3, 4-dihydroxyphenylacetaldehyde", ACS Chem Neurosci, 10, pp.690~703 (2019)
34. Wang S, "Quantitative proteomics identifies altered O-GlcNAcylation of structural, synaptic and memory-associated proteins in Alzheimer’s disease", J Pathol, 243, pp.78~88 (2017)
35. Li Y, "Amyloid fibril structure of alpha-synuclein determined by cryo-electron microscopy", Cell Res, 28, pp.897~903 (2018)
36. Tuttle MD, "Solid-state NMR structure of a pathogenic fibril of fulllength human alpha-synuclein", Nat Struct Mol Biol, 23, pp.409~415 (2016)
37. Alfaro JF, "Tandem mass spectrometry identifies many mouse brain O-GlcNAcylated proteins including EGF domain-specific O-GlcNAc transferase targets", Proc Natl Acad Sci U S A, 109, pp.7280~7285 (2012)
38. Morris M, "Tau posttranslational modifications in wild-type and human amyloid precursor protein transgenic mice", Nat Neurosci, 18, pp.1183~1189 (2015)
39. Zhang J, "Enzymatic O-GlcNAcylation of alpha-synuclein reduces aggregation and increases SDS-resistant soluble oligomers", Neurosci Lett, 655, pp.90~94 (2017)
40. Levine PM, "alphaSynuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson’s disease", Proc Natl Acad Sci U S A, 116, pp.1511~1519 (2019)
41. Marotta NP, "O-GlcNAc modification blocks the aggregation and toxicity of the protein alpha-synuclein associated with Parkinson’s disease", Nat Chem, 7, pp.913~920 (2015)
42. Marotta NP, "O-GlcNAc modification prevents peptide-dependent acceleration of alpha-synuclein aggregation", ChemBioChem, 13, pp.2665~2670 (2012)
43. Ryan P, "O-GlcNAc modification protects against protein misfolding and aggregation in neurodegenerative disease", ACS Chem Neurosci, 10, pp.2209~2221 (2019)
44. Lewis YE, "O-GlcNAcylation of alpha-synuclein at serine 87 reduces aggregation without affecting membrane binding", ACS Chem Biol, 12, pp.1020~1027 (2017)
45. Vicente Miranda H, "Glycation potentiates alpha-synuclein-associated neurodegeneration in synucleinopathies", Brain, 140, pp.1399~1419 (2017)
46. Chen L, "Ribosylation rapidly induces alpha-synuclein to form highly cytotoxic molten globules of advanced glycation end products", PLoS One, 5, pp.e9052~ (2010)
47. Sharma N, "The deglycase activity of DJ-1 mitigates alpha-synuclein glycation and aggregation in dopaminergic cells : Role of oxidative stress mediated downregulation of DJ-1 in Parkinson’s disease", Free Radic Biol Med, 135, pp.28~37 (2019)
48. Marino L, "Unravelling the effect of N(epsilon)-(carboxyethyl)lysine on the conformation, dynamics and aggregation propensity of alpha-synuclein", Chem Sci, 11, pp.3332~3344 (2020)
49. Lee D, "The modification of alpha-synuclein by dicarbonyl compounds inhibits its fibril-forming process", Biochim Biophys Acta, 1794, pp.421~430 (2009)
50. Sevcsik E, "Allostery in a disordered protein : oxidative modifications to alpha-synuclein act distally to regulate membrane binding", J Am Chem Soc, 133, pp.7152~7158 (2011)
51. Burai R, "Elucidating the role of site-specific nitration of alphasynuclein in the pathogenesis of Parkinson’s disease via protein semisynthesis and mutagenesis", J Am Chem Soc, 137, pp.5041~5052 (2015)
52. Giasson BI, "Oxidative damage linked to neurodegeneration by selective alphasynuclein nitration in synucleinopathy lesions", Science, 290, pp.985~989 (2000)
53. Hodara R, "Functional consequences of alpha-synuclein tyrosine nitration : diminished binding to lipid vesicles and increased fibril formation", J Biol Chem, 279, pp.47746~47753 (2004)
54. Norris EH, "Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications", J Biol Chem, 278, pp.27230~27240 (2003)
55. Qiao HH, "Implications of alpha-synuclein nitration at tyrosine 39 in methamphetamine-induced neurotoxicity in vitro and in vivo", Neural Regen Res, 14, pp.319~327 (2019)
56. Yamin G, "Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers", FEBS Lett, 542, pp.147~152 (2003)
57. Fujiwara H, "alphaSynuclein is phosphorylated in synucleinopathy lesions", Nat Cell Biol, 4, pp.160~164 (2002)
58. Nakajo S, "A new brain-specific 14-kDa protein is a phosphoprotein. Its complete amino acid sequence and evidence for phosphorylation", Eur J Biochem, 217, pp.1057~1063 (1993)
59. Pronin AN, "Synucleins are a novel class of substrates for G protein-coupled receptor kinases", J Biol Chem, 275, pp.26515~26522 (2000)
60. Chen L, "Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease", Nat Neurosci, 8, pp.657~663 (2005)
61. Chen L, "Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation", J Clin Invest, 119, pp.3257~3265 (2009)
62. Sato H, "Authentically phosphorylated alpha-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson’s disease", J Neurosci, 31, pp.16884~16894 (2011)
63. Okochi M, "Constitutive phosphorylation of the Parkinson’s disease associated alpha-synuclein", J Biol Chem, 275, pp.390~397 (2000)
64. Paleologou KE, "Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions", J Neurosci, 30, pp.3184~3198 (2010)
65. Prasad V, "Monitoring alpha-synuclein multimerization in vivo", FASEB J, 33, pp.2116~2131 (2019)
66. Smith WW, "Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells", J Neurosci, 25, pp.5544~5552 (2005)
67. Waxman EA, "Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein", J Neuropathol Exp Neurol, 67, pp.402~416 (2008)
68. Mbefo MK, "Phosphorylation of synucleins by members of the Pololike kinase family", J Biol Chem, 285, pp.2807~2822 (2010)
69. Ding J, "Role of alphasynuclein phosphorylation at Serine 129 in methamphetamine-induced neurotoxicity in vitro and in vivo", Neuroreport, 31, pp.787~797 (2020)
70. Oueslati A, "Polo-like kinase 2 regulates selective autophagic alpha-synuclein clearance and suppresses its toxicity in vivo", Proc Natl Acad Sci U S A, 110, pp.E3945~ (2013)
71. 신우현, "Death-associated Protein Kinase 1 Phosphorylates α-Synuclein at Ser129 and Exacerbates Rotenone-induced Toxic Aggregation of α-Synuclein in Dopaminergic SH-SY5Y Cells", Experimental Neurobiology, 29(3), pp.207~218 (2020), 한국뇌신경과학회[DOI]
72. Nakamura T, "Activated Fyn phosphorylates alpha-synuclein at tyrosine residue 125", Biochem Biophys Res Commun, 280, pp.1085~1092 (2001)
73. Ellis CE, "alpha-synuclein is phosphorylated by members of the Src family of protein-tyrosine kinases", J Biol Chem, 276, pp.3879~3884 (2001)
74. Negro A, "Multiple phosphorylation of alphasynuclein by protein tyrosine kinase Syk prevents eosininduced aggregation", FASEB J, 16, pp.210~212 (2002)
75. Sorrentino ZA, "Carboxy-terminal truncation and phosphorylation of alphasynuclein elongates survival in a prion-like seeding mouse model of synucleinopathy", Neurosci Lett, 732, pp.135017~ (2020)
76. Oueslati A, "Mimicking phosphorylation at serine 87 inhibits the aggregation of human alpha-synuclein and protects against its toxicity in a rat model of Parkinson’s disease", J Neurosci, 32, pp.1536~1544 (2012)
77. Stefanis L, "How is alpha-synuclein cleared from the cell?", J Neurochem, 150, pp.577~590 (2019)
78. Shin Y, "The co-chaperone carboxyl terminus of Hsp70-interacting protein(CHIP)mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways", J Biol Chem, 280, pp.23727~23734 (2005)
79. TetzlaffJE, "CHIP targets toxic alpha-Synuclein oligomers for degradation", J Biol Chem, 283, pp.17962~17968 (2008)
80. Davies SE, "Enhanced ubiquitin-dependent degradation by Nedd4 protects against alpha-synuclein accumulation and toxicity in animal models of Parkinson’s disease", Neurobiol Dis, 64, pp.79~87 (2014)
81. Tofaris GK, "Ubiquitin ligase Nedd4 promotes alpha-synuclein degradation by the endosomal-lysosomal pathway", Proc Natl Acad Sci U S A, 108, pp.17004~17009 (2011)
82. Meier F, "Semisynthetic, site-specific ubiquitin modification of alpha-synuclein reveals differential effects on aggregation", J Am Chem Soc, 134, pp.5468~5471 (2012)
83. Hejjaoui M, "Towards elucidation of the role of ubiquiti-nation in the pathogenesis of Parkinson’s disease with semisynthetic ubiquitinated alpha-synuclein", Angew Chem Int Ed Engl, 50, pp.405~409 (2011)
84. Gerez JA, "A cullin-RING ubiquitin ligase targets exogenous alpha-synuclein and inhibits Lewy body-like pathology", Sci Transl Med, 11, pp.eaau6722~ (2019)
85. Ye Y, "N-terminal ubiquitination of amyloidogenic proteins triggers removal of their oligomers by the proteasome holoenzyme", J Mol Biol, 432, pp.585~596 (2020)
86. Moon SP, "Ubiquitination can change the structure of the alpha-synuclein amyloid fiber in a site selective fashion", J Org Chem, 85, pp.1548~1555 (2020)
87. Haj-Yahya M, "Synthetic polyubiquitinated alpha-Synuclein reveals important insights into the roles of the ubiquitin chain in regulating its pathophysiology", Proc Natl Acad Sci U S A, 110, pp.17726~17731 (2013)
88. Pountney DL, "SUMO-1marks the nuclear inclusions in familial neuronal intranuclear inclusion disease", Exp Neurol, 184, pp.436~446 (2003)
89. Rott R, "SUMOylation and ubiquitination reciprocally regulate alpha-synuclein degradation and pathological aggregation", Proc Natl Acad Sci U S A, 114, pp.13176~13181 (2017)
90. Kim YM, "Proteasome inhibition induces alpha-synuclein SUMOylation and aggregate formation", J Neurol Sci, 307, pp.157~161 (2011)
91. Abeywardana T, "Extent of inhibition of alpha-synuclein aggregation in vitro by SUMOylation is conjugation site-and SUMO isoform-selective", Biochemistry, 54, pp.959~961 (2015)
92. Shahpasandzadeh H, "Interplay between sumoylation and phosphorylation for protection against alpha-synuclein inclusions", J Biol Chem, 289, pp.31224~31240 (2014)
93. Krumova P, "Sumoylation inhibits alpha-synuclein aggregation and toxicity", J Cell Biol, 194, pp.49~60 (2011)
94. Baba M, "Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies", Am J Pathol, 152, pp.879~884 (1998)
95. Muntane G, "alpha-synuclein phosphorylation and truncation are normal events in the adult human brain", Neuroscience, 200, pp.106~119 (2012)
96. Campbell BC, "The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson’s disease", J Neurochem, 76, pp.87~96 (2001)
97. Iyer A, "C-terminal truncated alphasynuclein fibrils contain strongly twisted beta-sheets", J Am Chem Soc, 139, pp.15392~15400 (2017)
98. Hoyer W, "Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro", Biochemistry, 43, pp.16233~16242 (2004)
99. Mishizen-Eberz AJ, "Cleavage of alpha-synuclein by calpain : potential role in degradation of fibrillized and nitrated species of alphasynuclein", Biochemistry, 44, pp.7818~7829 (2005)
100. Mishizen-Eberz AJ, "Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro", J Neurochem, 86, pp.836~847 (2003)
101. Kasai T, "Cleavage of normal and pathological forms of alpha-synuclein by neurosin in vitro", Neurosci Lett, 436, pp.52~56 (2008)
102. Terada M, "The effect of truncation on prion-like properties of alpha-synuclein", J Biol Chem, 293, pp.13910~13920 (2018)
103. Munch G, "Crosslinking of alpha-synuclein by advanced glycation endproducts--an early pathophysiological step in Lewy body formation?", J Chem Neuroanat, 20, pp.253~257 (2000)
104. Brahmachari S, "Activation of tyrosine kinase c-Abl contributes to alpha-synuclein-induced neurodegeneration", J Clin Invest, 126, pp.2970~2988 (2016)
105. Rott R, "Monoubiquitylation of alpha-synuclein by seven in absentia homolog(SIAH)promotes its aggregation in dopaminergic cells", J Biol Chem, 283, pp.3316~3328 (2008)
106. Lee JT, "Ubiquitination of alpha-synuclein by Siah-1 promotes alphasynuclein aggregation and apoptotic cell death", Hum Mol Genet, 17, pp.906~917 (2008)
107. Oh Y, "Human Polycomb protein 2 promotes alpha-synuclein aggregate formation through covalent SUMOylation", Brain Res, 1381, pp.78~89 (2011)
108. Vijayakumaran S, "Ginkgolic acid promotes autophagy-dependent clearance of intracellular alpha-synuclein aggregates", Mol Cell Neurosci, 101, pp.103416~ (2019)
109. Periquet M, "Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo", J Neurosci, 27, pp.3338~3346 (2007)
110. Li W, "Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson’s disease-linked mutations", Proc Natl Acad Sci U S A, 102, pp.2162~2167 (2005)
111. Zhang Z, "Asparagine endopeptidase cleaves alpha-synuclein and mediates pathologic activities in Parkinson’s disease", Nat Struct Mol Biol, 24, pp.632~642 (2017)
112. McGlinchey RP, "C-terminal alpha-synuclein truncations are linked to cysteine cathepsin activity in Parkinson’s disease", J Biol Chem, 294, pp.9973~9984 (2019)
113. Dufty BM, "Calpaincleavage of alpha-synuclein : connecting proteolytic processing to disease-linked aggregation", Am J Pathol, 170, pp.1725~1738 (2007)
114. Serpell LC, "Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation", Proc Natl Acad Sci U S A, 97, pp.4897~4902 (2000)
115. Tofaris GK, "Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120) : implications for Lewy body disorders", J Neurosci, 26, pp.3942~3950 (2006)
116. Murray IV, "Role of alpha-synuclein carboxy-terminus on fibril formation in vitro", Biochemistry, 42, pp.8530~8540 (2003)
117. Ni X, "Structural insights into alpha-synuclein fibril polymorphism : Effects of Parkinson’s disease-related C-terminal truncations", J Mol Biol, 431, pp.3913~3919 (2019)
118. van der Wateren IM, "C-terminal truncation of alpha-synuclein promotes amyloid fibril amplification at physiological pH", Chem Sci, 9, pp.5506~5516 (2018)
119. Anderson JP, "Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease", J Biol Chem, 281, pp.29739~29752 (2006)
120. Luk KC, "Exogenous alpha-synuclein fibrils seed the formation of Lewy bodylike intracellular inclusions in cultured cells", Proc Natl Acad Sci U S A, 106, pp.20051~20056 (2009)
121. Waxman EA, "Characterization of kinases involved in the phosphorylation of aggregated alpha-synuclein", J Neurosci Res, 89, pp.231~247 (2011)
122. Machiya Y, "Phosphorylated alpha-synuclein at Ser-129 is targeted to the proteasome pathway in a ubiquitin-independent manner", J Biol Chem, 285, pp.40732~40744 (2010)
123. Moons R, "Metal ions shape alpha-synuclein", Sci Rep, 10, pp.16293~ (2020)
124. Burmann BM, "Regulation of alpha-synuclein by chaperones in mammalian cells", Nature, 577, pp.127~132 (2020)

관련 논문AI추천